AHA/ASA guideline recommendations for prevention of stroke in women menopause and postmenopausal hormonal therapy

< AHA
Jump to: navigation, search

Stroke Main page

Patient Information

Overview

Causes

Classification

Hemorrhagic stroke
Ischemic stroke

Differential Diagnosis

Epidemiology and Demographics

Diagnosis

NIH stroke scale
Glasgow coma scale

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ayokunle Olubaniyi, M.B,B.S [2]

2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT)[1]

Postmenopausal Hormonal Therapy

Class III (No Benefit)
"1. HT (CEE with or without medroxyprogesterone) should not be used for primary or secondary prevention of stroke in postmenopausal women. (Level of Evidence: A) "
"2. Selective estrogen receptor modulators, such as raloxifene, tamoxifen, or tibolone, should not be used for primary prevention of stroke. (Level of Evidence: A) "

References

  1. Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL; et al. (2014). "Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association". Stroke. doi:10.1161/01.str.0000442009.06663.48. PMID 24503673.


Cardiology


Linked-in.jpg